Google
TEM Stock Analysis — TEMPUS AI, INC. CLASS A COMMON STOCK (Healthcare >> Health Information Services)
TEM FAQ
What is TEM's ROE?
TEMPUS AI, INC. CLASS A COMMON STOCK reports a Return on Equity (ROE) of -72.74%.
What is TEM's dividend yield?
TEMPUS AI, INC. CLASS A COMMON STOCK offers a dividend yield of 0.00%.
What is TEM's Quality Score?
Our AI rates TEM's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TEM?
Our AI Timing Score for TEM is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TEM belong to?
TEMPUS AI, INC. CLASS A COMMON STOCK is classified under the Healthcare >> Health Information Services sector on the NASDAQ exchange
TEM AI Analysis Summary
Our AI summary for TEM: TEMPUS AI, INC. CLASS A COMMON STOCK (NASDAQ), Healthcare >> Health Information Services sector. The stock currently trades at a P/E of 0.00, ROE of -72.74%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 43.87
Price
-0.42
(-0.95%)
Day Change
|
|
|---|
TEM, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 43.87 |
| PBV / Sector |
19.15 / 6.33
|
| Earning Per Share | -1.67 |
| PE / Sector |
N/A / 46.50
|
| PEG or PE/Growth / Sector |
N/A / -0.41
|
| Average 1M Daily Value |
251.29 M
GREAT
|
| Average 1W Daily Value |
259.31 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
64% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:34 |
| Symbol | TEM |
| Name | TEMPUS AI, INC. CLASS A COMMON STOCK |
| Sector | Healthcare >> Health Information Services |
| Market | NASDAQ |
| Listed Shares | 175.02 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 7,974.89 / 4,079.00 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 600 West Chicago Avenue, Chicago, IL, United States, 60654
Phone: 800 976 5448
Website: https://www.tempus.com
Employees: 3,800
Description: Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Health Information Services
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Health Information ServicesAnalysed on the same criteria, ordered by market cap